Biotech / Medical | Biotech Valuation


Previous 10 | Next 10 
To: Ian@SI who wrote (25151)12/7/2007 3:34:32 PM
From: Biomaven   of 40275
 
FWIW, I cross-examined a neighbor who is an academic-type cardiologist on the prospects for this type of atrial fib drug. He said that modern practice is pretty much to concentrate on rate-control and generally not even bother with attempts at cardioversion, so he didn't sound particularly enthused, although he wasn't familiar with the specifics of V.

I'm guessing some sort of approval on acute use is mostly baked into the stock here, although I haven't been following the story much of late. Just didn't feel like a good risk/reward play - one of those +25% at best if all goes well deals (at least on the short-term use indication).

Peter

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

From: rkrw12/7/2007 6:30:31 PM
   of 40275
 
A biotech valuation observation, gild is catching up to Amgen.

Top 3 biotechs:

Dna $73B
Amgn $59B
Gild $46B

Share Recommend | Keep | Reply | Mark as Last Read

From: marcello412/7/2007 10:18:11 PM
   of 40275
 
Spoke to you about Noveko a couple of months back! tsx-v
I was punished for predicting a big increase was 2.50$
Now 10.19$
Are any of you guys in?
And Is Henry Schein in too? Yet!

Share Recommend | Keep | Reply | Mark as Last Read

To: WilderElisimo who wrote (25152)12/7/2007 10:46:58 PM
From: Robohogs   of 40275
 
Which strikes? I have a hard time handicapping things right now, esp. with the full FDA to come later in January.

I had been conversing with a few other biofreaks on ways to play this. I do wish I had bought some puts/shorted stock/sold calls on the open when I could not figure out why stock was up. That being said, right play now is probably going long as the panel will likely vote yes although with smaller population/more hurdles. Do not know what it means for chronic oral use.

Jon

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (2)

To: Biomaven who wrote (25154)12/7/2007 10:51:25 PM
From: Robohogs   of 40275
 
I figure ultimately (after FDA decision not panel):

$12ish on approval
10ish if limited approval
$6-7ish on approvable
$3-4ish on full new Ph III
$2 on not approvable.

Jon

PS Short 5 7.50 puts (from about 100 when vols were higher and I was getting well over a buck a few months back) and short 30 12.50 calls. If a panel recommendation comes down for approval, I would expect spike to $11-13 and I will be fine. If not recommending approval, should be $5ish and I will be fine due to ratios used.

Share Recommend | Keep | Reply | Mark as Last Read

From: Arthur Radley12/8/2007 6:31:35 PM
   of 40275
 
OT:

A kiss begins with K..........

cnn.com 

Share Recommend | Keep | Reply | Mark as Last Read

To: Robohogs who wrote (25157)12/8/2007 7:56:26 PM
From: WilderElisimo   of 40275
 
no message.

Share Recommend | Keep | Reply | Mark as Last Read

To: Robohogs who wrote (25157)12/8/2007 8:01:24 PM
From: WilderElisimo   of 40275
 
Dec 10s at a buck. Will offer them back GTC at $2. I don't plan on holding them past Wed. I think V gets a positive panel vote and the companion drug's briefing dox will make it look good.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: WilderElisimo who wrote (25161)12/8/2007 10:44:40 PM
From: Robohogs   of 40275
 
Same ones I am looking at. Good luck and wish me luck in buying some.

Jon

Share Recommend | Keep | Reply | Mark as Last Read

From: tom pope12/9/2007 9:06:37 AM
   of 40275
 
OT, but relevant to the discussion here a few days ago. From Mauldin's weekly letter:

In fact, let me sound a note of "optimism." The ever-growing estimates of losses due to subprime may be overstated. According to a study by Goldman Sachs, the ABX indexes suggest about $400 billion in losses. But a $150 billion dollar chunk of that is from AAA rated bonds. They have been marked down an average of 18%. But in order for the AAA tranches to lose money, 50% of the mortgages in the securities would have to go into foreclosure, and those homes would have to drop 50% in value.

So, why the drop in value? Because some of the Residential Mortgage Backed Securities will more than likely face such a serious loss. Others are unlikely to see anywhere close to a 50% foreclosure rate. The problem is that investors cannot figure out which RMBS's are in trouble and which would be good bets. Until there is transparency, it is likely that prices will stay low.

Share Recommend | Keep | Reply | Mark as Last Read
Previous 10 | Next 10 

Copyright © 1995-2013 Knight Sac Media. All rights reserved.